Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
Public ClinicalTrials.gov record NCT00985192. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well everolimus works in treating patients with previously treated unresectable or metastatic esophageal cancer or stomach cancer.
Study identification
- NCT ID
- NCT00985192
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 49 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2009
- Primary completion
- Apr 30, 2014
- Completion
- Apr 30, 2014
- Last update posted
- Aug 4, 2020
2009 – 2014
United States locations
- U.S. sites
- 18
- U.S. states
- 3
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Central Hematology Oncology Medical Group, Inc. | Alhambra | California | 91801 | — |
| Comprehensive Blood and Cancer Center | Bakersfield | California | 93309 | — |
| St. Jude Heritage Medical Group at Virginia K. Crosson Cancer Center | Fullerton | California | 92835 | — |
| Antelope Valley Cancer Center | Lancaster | California | 93534 | — |
| Pacific Shores Medical Group | Long Beach | California | 90813 | — |
| Jonsson Comprehensive Cancer Center at UCLA | Los Angeles | California | 90095-1781 | — |
| Translational Oncology Research International (TORI) Network | Los Angeles | California | 90095 | — |
| North Valley Hematology/Oncology Medical Group | Northridge | California | 91328 | — |
| Wilshire Oncology Medical Group, Inc. | Pomona | California | 91767 | — |
| Cancer Care Associates Medical Group, Inc. | Redondo Beach | California | 90277 | — |
| TORI REDONDO BEACH (Cancer Care Associates Medical Group, Inc.) | Redondo Beach | California | 90277 | — |
| Sansum Medical Clinic | Santa Barbara | California | 93105 | — |
| Santa Barbara Hematology Oncology Medical Group, Inc. | Santa Barbara | California | 93105 | — |
| Central Coast Medical Oncology Corporation | Santa Maria | California | 93454 | — |
| Trivalley Oncology Hematology | Westlake Village | California | 91361 | — |
| Suburban Hematology-Oncology Associates, P.A. | Lawrenceville | Georgia | 30045 | — |
| Northwest Georgia Oncology Centers, P.C. | Marietta | Georgia | 30060 | — |
| Comprehensive Cancer Centers of Nevada | Las Vegas | Nevada | 89109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Gastric Cancer trials
Other public records listing Gastric Cancer. Sorted by last update posted; newest first. Not a recommendation.
- NCT03526835: A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors Recruiting
- NCT04069273: Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma Active, not recruiting
- NCT05208762: A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors Recruiting
- NCT07705334: A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors Recruiting
- NCT06580002: Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial Recruiting
- NCT07529808: Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00985192, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 4, 2020 · Synced Sep 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00985192 live on ClinicalTrials.gov.